Stocks · Healthcare · Biotechnology
Exelixis, Inc. EXEL
$58.39 +0.78% Close, Oct 2, 2026 · NASDAQ · Market cap $14.68B
Strong growthHigh qualityStrong trendInexpensive vs sectorLow risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $3.19, up 54.1% year over year.
- Earnings beat analyst estimates in each of the last 9 quarters (average surprise over the last four: +14.1%).
- The diluted share count fell 8.7% in a year, mainly through buybacks.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 49%
- EPS growth (TTM, YoY)Top 26%
- FCF growth (TTM, YoY)Top 26%
- Revenue growth, 3-year CAGRTop 43%
- Revenue growth accelerationTop 16%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 2%
- Gross marginTop 12%
- Operating marginTop 3%
- Cash conversion (OCF / net income)Bottom 39%
- Accruals (lower is better)Top 25%
- Net debt / EBITDA (lower is better)Top 32%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 9%
- Free-cash-flow yieldTop 10%
- EBITDA / enterprise valueTop 16%
- Sales / enterprise valueBottom 44%
- P/E vs own 5-year history (lower is better)Top 36%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 37%
- 6-month returnTop 30%
- 1-year return vs S&P 500Top 30%
- Distance from 52-week highTop 5%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 32%
- Consecutive EPS beatsTop 7%
- Share of analysts rating BuyBottom 14%
- Upside to consensus price targetBottom 6%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 15%
- Maximum drawdown, 3 yearsTop 3%
- Beta vs S&P 500 (lower is better)Top 39%
- Net debt / EBITDA (lower is better)Top 32%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3.3% | 9.2% | ↑ |
| EPS growth (YoY) | 37.9% | 54.1% | ↑ |
| Gross margin | 96.6% | 96.5% | ↓ |
| Operating margin | 31.4% | 39.9% | ↑ |
| FCF margin | 32.4% | 47.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 9.2% | 3.3% | ↑ | Top 49% |
| EPS growth (TTM, YoY) | 54.1% | 37.9% | ↑ | Top 26% |
| Gross margin | 96.5% | 96.6% | ↓ | Top 12% |
| Operating margin | 39.9% | 31.4% | ↑ | Top 3% |
| Net margin | 35.3% | 27.0% | ↑ | — |
| Free-cash-flow margin | 47.5% | 32.4% | ↑ | — |
| Return on invested capital | 37.9% | — | Top 2% | |
| Revenue growth, 3-year CAGR | 12.9% | — | Top 43% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.38×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -12.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +5.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.11×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 7.36%
- Shareholder yield
- 7.36%
- Share count change, 1 year
- -8.7%
- Share count change, 3-year CAGR
- -7.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jul 3, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 9
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +14.1%
- Average 2-day reaction, last 8
- -0.6%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $51.78
- Target vs current price
- -11.3%
- Analysts with a rating
- 33
- Share rating Buy or Strong Buy
- 48%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +6.7% | +1.2% | -8.3% | +1.6% | — |
| May 5, 2026 | +13.7% | +0.6% | +12.5% | +9.9% | +26.7% |
| Feb 10, 2026 | +22.1% | -2.2% | +0.3% | -6.1% | +10.8% |
| Nov 4, 2025 | +13.9% | -0.4% | +8.8% | +14.1% | +8.7% |
| Jul 28, 2025 | +15.4% | -2.7% | -18.3% | -15.3% | -24.3% |
| May 13, 2025 | +73.1% | -0.1% | +20.8% | +15.0% | +1.1% |
| Feb 11, 2025 | +7.8% | -2.1% | +2.1% | +10.2% | +9.9% |
| Oct 29, 2024 | +14.3% | +0.8% | +20.3% | +27.6% | +14.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.91 | $0.85 | +6.7% | $628.7M |
| May 5, 2026 | $0.87 | $0.77 | +13.7% | $610.8M |
| Feb 10, 2026 | $0.94 | $0.77 | +22.1% | $598.7M |
| Nov 4, 2025 | $0.78 | $0.69 | +13.9% | $597.8M |
| Jul 28, 2025 | $0.75 | $0.65 | +15.4% | $568.3M |
| May 13, 2025 | $0.62 | $0.36 | +73.1% | $555.4M |
| Feb 11, 2025 | $0.55 | $0.51 | +7.8% | $566.8M |
| Oct 29, 2024 | $0.40 | $0.35 | +14.3% | $539.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 18.3× | 21.5× | 29th | Top 9% |
| P/E (forward) | 16.6× | — | — | — |
| EV / EBITDA | 14.0× | — | — | Top 16% |
| EV / Sales | 5.98× | — | — | Bottom 44% |
| Free-cash-flow yield | 7.89% | — | — | Top 10% |
| Earnings yield | 5.46% | — | — | Top 9% |
P/E over the past five years
Range 14.7× – 75.1× since Jul 2, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +41.7%
- Earnings per share growth (TTM)
- +54.1%
- Change in P/E multiple
- -17.1%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 24
- Days above the 200-day average
- 130
- 50-day average slope (20 days)
- +1.6%
- 200-day average slope (20 days)
- +3.2%
- Distance from 50-day average
- +4.6%
- Distance from 200-day average
- +19.0%
- RSI (14)
- 56.1
- Relative volume
- 0.93×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 34.0%
- Volatility vs own 5-year history
- 47th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.94
- Correlation with S&P 500
- 0.36
- Current drawdown from 1-year high
- -1.3%
- Maximum drawdown, 3 years
- -25.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| May 14, 2021 | Oct 10, 2022 | -41.5% | 354 days | 458 days (Aug 7, 2024) |
| Oct 8, 2020 | Nov 23, 2020 | -25.8% | 32 days | 33 days (Jan 12, 2021) |
| May 15, 2025 | Oct 20, 2025 | -25.3% | 108 days | 45 days (Dec 23, 2025) |
| Jan 12, 2021 | Mar 4, 2021 | -15.5% | 35 days | 49 days (May 13, 2021) |
| Jan 15, 2025 | Jan 24, 2025 | -13.1% | 6 days | 22 days (Feb 26, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $14.68B
- P/E (TTM)
- 18.3
- EPS, diluted (TTM)
- $3.19
- Revenue (TTM)
- $2.44B
- 52-week range
- $33.76 – $61.14
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.43B | $1.61B | $1.83B | $2.17B | $2.32B |
| Gross profit | $1.38B | $1.55B | $1.76B | $2.09B | $2.24B |
| Operating income | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Net income | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| EPS (diluted) | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M | $610.8M | $628.7M |
| Net income | $118.0M | $139.9M | $159.6M | $184.8M | $193.6M | $244.5M | $210.5M | $212.1M |
| EPS (diluted) | $0.40 | $0.47 | $0.55 | $0.65 | $0.70 | $0.88 | $0.79 | $0.82 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Capital expenditure | -$64.2M | -$138.5M | -$163.0M | -$66.2M | -$39.9M |
| Free cash flow | $336.6M | $224.2M | $170.4M | $633.8M | $844.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $23.9M | -$516.9M | -$590.2M | -$898.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $839.4M
- Total assets
- $2.49B
- Total liabilities
- $650.5M
- Total debt
- $165.9M
- Net debt
- -$115.5M
- Shareholders’ equity
- $1.84B
As of Jul 3, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 26,400,456
- Days to cover
- 12.38
- Change vs previous report
- -7.9%
FINRA short interest, settlement date Sep 15, 2026.